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Doortje Engel, MD, PhD, Clay Goodman, MD, Katrina Gwinn, MD, Timothy D. Veenstra, PhD,
Geoffrey Ling, MD, PhD, Andrew K. Ottens, PhD, Frank Tortella, PhD, Ronald L. Hayes, PhD
ABSTRACT. Manley GT, Diaz-Arrastia R, Brophy M, Engel
D, Goodman C, Gwinn K, Veenstra TD, Ling G, Ottens AK,
Tortella F, Hayes RL. Common data elements for traumatic brain
injury: recommendations from the Biospecimens and Biomarkers
Working Group. Arch Phys Med Rehabil 2010;91:1667-72.
Recent advances in genomics, proteomics, and biotechnology
have provided unprecedented opportunities for translational re-
search and personalized medicine. Human biospecimens and
biofluids represent an important resource from which molecular
data can be generated to detect and classify injury and to identify
molecular mechanisms and therapeutic targets. To date, there has
been considerable variability in biospecimen and biofluid collec-
tion, storage, and processing in traumatic brain injury (TBI) stud-
ies. To realize the full potential of this important resource, stan-
dardization and adoption of best practice guidelines are required to
insure the quality and consistency of these specimens. The aim of
the Biospecimens and Biomarkers Working Group was to provide
recommendations for core data elements for TBI research and
develop best practice guidelines to standardize the quality and
accessibility of these specimens. Consensus recommendations
were developed through interactions with focus groups and input
from stakeholders participating in the interagency workshop on
Standardization of Data Collection in TBI and Psychological
Health held in Washington, DC, in March 2009. With the adop-
tion of these standards and best practices, future investigators will
be able to obtain data across multiple studies with reduced costs
and effort and accelerate the progress of genomic, proteomic, and
metabolomic research in TBI.
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BECAUSE GENOMIC AND PROTEOMIC research in TBIis still very much an emerging field, our goal was not to
recommend assays of specific protein biomarkers or polymor-
phisms as core data elements. The aim of the working group was
to provide recommendations for core biospecimen and biomarker
data elements for TBI research and develop best practice guide-
lines to standardize the quality and accessibility of these speci-
mens. We were also charged with establishing consensus for the
core specimen data elements that should be collected for every
TBI study and to identify supplemental and emerging data ele-
ments for more advanced and extended studies.
APPROACH
Multiple group conference calls were held as well as a number
of smaller group calls and e-mail interactions. There was universal
agreement on the need for standardization and development of
best practices for collecting, processing, and storing biospecimens
and biofluids. Past, current, and future efforts in civilian and
military TBI biomarker genomics and proteomics research were
reviewed and discussed.
Two series of observations support the fundamental hypoth-
esis that genetic factors significantly influence functional out-
come after TBI. The first of these is the finding that inheritance
of the APOE-e4 allele is associated with poor outcome after
TBI.1,2 The effect size of inheritance of one APOE-e4 allele is
modest, with the odds ratio of an unfavorable outcome ranging
from 3.57 to 13.93. While these and other studies have primar-
ily focused on 6-month outcome,3 there is evidence that the
APOE-e4 genotype may also be associated with long-term
outcome and cognitive decline after TBI.4 Thus, this polymor-
phism may be relevant in the patient with chronic as well as
acute TBI. Polymorphisms in the interleukin-1 system have
also been associated with outcome after TBI, but these studies
have not so far been replicated.5 It is likely that the small
sample sizes used in studies to date are a factor in false-
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negative and even false-positive findings.6 Although APOE-e4
appears to be the most likely candidate for the first “Core”
genomic biomarker for TBI, future studies with sufficient pa-
tient numbers and comprehensive phenotyping are needed.
There are also recent examples of discovery-driven proteomic
studies focused on finding effective biomarkers for TBI.7,8
Mass spectrometry has been the primary proteomic technology
and has revolutionized the ways that biomarker discovery is
being conducted in this field.
Genomic biomarkers may also be relevant to psychologic
health issues associated with TBI. For example, the COMT gene
plays a key role in the degradation of dopamine in the frontal
cortex. The Val158Met polymorphism in the COMT gene has been
associated with neuropsychiatric phenotypes and cognition.9,10
The Val158Met genotype has also been associated with executive
functioning in patients with TBI.11 Recent studies have also iden-
tified an association between serotonin transporter genotype and
posttraumatic stress disorder,12 suggesting that this and other
polymorphisms may help us understand the complicated interre-
lationship between TBI and psychologic health.
It was the consensus of the group that while there is signif-
icant potential for large-scale genomics and proteomics in TBI,
there is sufficient variability in TBI biospecimen collection,
processing, and storage that must be addressed to advance the
field.13,14 Prospective clinical trials are an ideal setting in
which to collect DNA and biological fluids in sufficiently large
sample sizes associated with carefully collected clinical data to
allow successful genomic and proteomic studies.
A due diligence process was carried out to explore similar
efforts in other fields. A number of groups have already developed
best practice guidelines for biospecimen resources.15-18 These
documents provide general principles that can be used to guide the
design of studies in which biospecimens will be analyzed. There
was general agreement that much of the groundwork for the TBI
biospecimen working group had been provided by these prior
efforts. It was acknowledged that the group should not reinvent the
wheel, but it was also recognized that there are issues particular to
TBI that should be considered and addressed. The group felt that
a document that built on past efforts and incorporated issues
relevant to TBI would be an important contribution to the litera-
ture and the research community. Based on the members’ indi-
vidual expertise, the participants divided into subgroups to address
various aspects of biofluid and biomarker specimen collection,
storage, and processing. Preliminary recommendations were de-
veloped through e-mail interactions with the focus groups and
discussed in person with the working group members at the
interagency workshop on Standardization of Data Collection in
TBI and Psychological Health held in Washington, DC, in March
2009. The refined draft recommendations and best practices were
presented to stakeholders and other working groups during the
workshop for additional input. These comments and suggestions
have also been incorporated in the current recommendations. The
product of the Biospecimens and Biomarkers Working Group is,
by its nature, different from the other TBI CDE Working Group
articles in that the focus is best practices with step-by-step proto-
cols to standardize sample collection, processing, and storage.
RECOMMENDATIONS FOR COMMON
DATA ELEMENTS FOR
BIOSPECIMENS AND BIOMARKERS
The following are the group’s recommendations for core
specimen data elements that should be collected for all studies.
The collection of supplemental and emerging data elements
recommended for more advanced and extended studies should
be encouraged, particularly in studies that are directed at a
molecular mechanism that the biomarker measures.
1. Core data element recommendations
a. Collection of DNA sample for genomic analysis
b. Collection of acute (24h) plasma sample for proteomic
and metabolomic analyses
2. Supplemental data element recommendations
a. Collection of serial plasma and serum samples for pro-
teomic analysis
b. Collection of cerebrospinal fluid samples for proteomic
analysis
3. Emerging data element recommendations
a. Collection of cerebral microdialysis samples
b. Collection of PBMCs for gene and protein expression
studies
The TBI CDE Working Group recommendations for DNA
guidelines for genomic analyses are presented in appendix 1.
The timing of DNA collection is less critical, even in patients
who have received a blood transfusion. Recommendations for
plasma and serum guidelines for proteomic and metabolomic
analyses are shown in appendix 2. The timing for acquiring
these samples is more complicated. An acute plasma sample
(defined as24h) was recommended by the Working Group as
“Core” for all TBI studies to provide the opportunity for the
identification of diagnostic and predictive biomarkers in large
series of patients. However, the frequency and duration of
serial sample collection is biomarker-dependent and cannot be
standardized at this time. Information regarding cerebrospinal
fluid guidelines and microdialysis guidelines can be found in
appendices 3 and 4, respectively. Each of these best practice
guidelines addresses the acquisition, processing, and storage of
the samples in sufficient detail to promote standardization.
FUTURE DIRECTIONS
Although these recommendations and best practices are vol-
untary, their adoption will lead to a new standardization that
will advance TBI research. To demonstrate the utility of these
recommendations and best practices, we propose a pilot study
to examine the feasibility of multicenter biomarker CDE col-
lection across the broad spectrum of TBI. Implementation of
biospecimen and biomarker best practices will also require
outreach and education to inform and engage the TBI research
community and solicit comments and feedback. The working
group believes that the recommendations and best practices for
TBI biospecimens and biomarkers will continue to evolve as
the field advances and potential biomarkers will one day be-
come core CDEs. Thus, there will be a need for ongoing
support for the TBI CDE effort.
APPENDIX 1: DNA GUIDELINES FOR
GENOMIC ANALYSES
I. Acquisition of blood biospecimens
A. Blood is collected through venipuncture by appropri-
ately trained personnel.
B. For isolation of genomic DNA from whole blood, col-
lection of 5 to 20mL using EDTA-containing Vacu-
tainer tubesa is suitable. Use of citrate or heparinized
tubes is also suitable.
C. Invert the sample 8 to 10 times to ensure proper mix-
ture of blood and anticoagulant.
D. For isolation of PBMCs for future preparation of lym-
phoblastoid cell lines or gene expression studies, col-
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lection of 5 to 10mL whole blood in LeucoPREP cell
separation tubes.a EDTA-containing vacutainer tubes
may be used if the processing laboratory can perform
Ficoll-Paqueb density gradient separation.
II. Local processing
A. Whole blood (in EDTA or LeucoPREP tubes) should be
maintained at room temperature until transfer to the lab-
oratory for processing. Studies have shown that packed
cell volume starts decreasing with EDTA addition as early
as 1 hour postcollection, so it is important to process the
specimen in a time-efficient manner.
B. Transport the original, unfrozen Vacutainer without
breaking the seal to the designated local genomics labo-
ratory (if available). The Vacutainer system best preserves
the integrity of the blood sample if it is not broken.
C. Because the expense of overnight shipping is justifiable
only when highly specialized procedures such as prep-
aration of lymphoblastoid cells lines are planned, the
most cost-effective approach when such procedures are
not required is to aliquot and freeze whole blood locally
for DNA isolation later.
i. Storage in aliquots of 1-mL to 2-mL freezer-safe
containers (ie, Cryovials) is most convenient.
ii. Multiple aliquots should be prepared in case of
mishaps during shipment or DNA isolation. This
also minimizes the freeze-thaw cycles should there
be a need for multiple analyses at interval times.
D. DNA isolation from whole blood. It is most cost-
efficient to isolate DNA from multiple (20–100 sam-
ples) at a time. This is most efficiently done by having
each of the clinical sites store samples locally until a
suitable number have been collected (ie, 10–20 sam-
ples). These can then be shipped in a single overnight
shipment to a central laboratory experienced in collec-
tion and banking of samples.
E. Preparation of lymphoblastoid cell lines. Overnight
shipment of LeucoPREP tubes to a laboratory experi-
enced in the viral transformation and preparation of
lymphoblastoid lines.
III. Local storage
A. Appropriate and complete documentation surrounding bio-
specimen collection, processing, and storage are essential and
will influence the quality of research data to be obtained.
B. Samples should be placed in nonfrost-free freezers at or
below –80°C. Frost-free freezers go through freeze-
thaw cycles that further damage the specimen.
C. Avoid any thawing of frozen samples. Thawing of
frozen samples of whole blood results in release of
deoxyribinucleases that destroy the DNA.
D. Centers at which samples are stored should institute a
back-up plan for freezer failure (eg, alternate power
source, dry ice, or liquid nitrogen). An appropriate alarm
system to support freezers for longtime storage is essen-
tial.
E. Lymphoblastoid cell lines must be stored in liquid
nitrogen. The Coriell Institute provides storage for
samples collected in National Institutes of Health–
sponsored studies (http://www.coriell.org).
F. An inventory system should be established for tracking
provenance of samples, including the time of collec-
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tion, processing, storage, and quality control proce-
dures carried out on each sample.
IV. Shipping
A. Deoxyribinucleases degradation begins after 2 to 3
days at room temperature, so fresh blood samples
should be shipped to the processing site within hours if
possible. If the genomics laboratory is not within reach
of local transport, frozen blood samples may be
shipped through a designated agency.
B. Dry ice or cold packs must accompany the frozen
specimen during air shipment. When dry ice is used,
the transport time should be minimized given that dry
ice sublimates at a rate of 2 to 5 kg per 24 hours
depending on the insulation of the shipment container.
C. Consult the local agency for proper shipping options
and certified transport materials. The International Air
Transportation Association (http://www.iata.org) and the
U.S. Department of Transportation (http://www.dot.gov)
have legal requirements governing the packaging, la-
beling, and shipping of biospecimens.
i. Category A infectious substances are capable of caus-
ing permanent disability or life-threatening or fatal
disease in humans or animals when exposure occurs.
ii. Category B infectious substances (also “diagnostic
specimens” or “clinical specimens”) are infectious
but do not meet the standard for category A inclu-
sion.
iii. Exempt patient specimens have a minimal likeli-
hood of containing pathogens.
D. Temperature loggers can be used to monitor tempera-
ture in shipments of samples to provide confirmation
and assurance that samples have been maintained at
appropriate temperatures.
V. Central storage
A. Appropriate and complete documentation surrounding
biospecimen collection, processing, storage, and ship-
ping from the individual sites is essential and will
influence the quality of the multicenter research data to
be obtained.
B. Bar code identification of samples with an automated
date and time stamp is recommended.
C. A formal plan for sharing the central biospecimen
resource is recommended.
D. The Central Storage Bank should maintain information
of laboratories where the samples have been sent to
avoid duplicative genotyping and inadvertent repetitive
reporting of data from the same patient.
E. The Central Storage Bank should also maintain infor-
mation regarding any stipulations regarding informed
consent for the use of the samples. For example, in
some studies, participants may provide permission for
their samples to be used only for studies on TBI.
APPENDIX 2: PLASMA AND SERUM GUIDELINES
FOR PROTEOMIC ANALYSES
I. Acquisition of blood biospecimens
A. For severely injured patients, blood is collected via
vascular access catheters that have been placed as part
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of the patients’ routine medical care. For other patients,
trained personnel collect blood through venipuncture.
B. For most purposes, 5 to 10mL whole blood will be
collected using a Vacutainer system. It should be noted
that the use of glass tubes can lead to low values for
certain analytes. For the most generalizable purposes,
polypropylene Vacutainer and subsequent storage tubes
are recommended.
II. Local processing (serum)
A. Blood samples should be collected in vacutainers that
contain no anticoagulant for the processing of serum.
B. Samples should be sat upright at room temperature for
30 minutes to allow for clotting. They then should be
spun at 4000rpm at room temperature for 5 to 7 min-
utes. The cleared serum should be pipetted and stored
in aliquots of 1 to 2mL.
C. Record the volume of each aliquot.
III. Local processing (plasma)
A. Blood samples should be collected in vacutainers that
contain EDTA when preparing plasma. Previous research
suggests that EDTA is the preferred anticoagulant because
others may interfere with analyte detection.19
i. The distinction between K2EDTA and K3EDTA
and their concentrations should be assessed. See
Goossens et al20 for more details.
B. Transport the original, unfrozen blood sample to the
designated local proteomics laboratory as soon as pos-
sible. Freezing has significant adverse effects on
plasma and its proteomic elements.
C. If specimens must be stored before processing, the
samples should sit on ice for 5 to 10 minutes. Samples
should be spun at 4000rpm at room temperature for 5 to
7 minutes. Plasma should be pipetted and stored in
aliquots of 500 L to 2mL.
D. Record the volume of each aliquot.
IV. Local documentation and storage
A. Appropriate and complete documentation surrounding
biospecimen collection, processing, and storage are es-
sential and will influence the quality of research data to
be obtained.
B. Bar code identification of samples with an automated
date and time stamp is recommended.
C. Samples should be placed in nonfrost-free freezers at or
below –80°C. Frost-free freezers go through freeze-
thaw cycles that further damage the specimen.
D. Centers at which samples are stored should institute a
back-up plan for freezer failure (eg, dry ice or liquid
nitrogen). An appropriate alarm system to support freezers
for longtime storage is essential.
E. An inventory system should be established for tracking
provenance of samples, including the time of collec-
tion, processing, storage, and quality control proce-
dures carried out on each sample.
V. Shipping
A. Dry ice or cold packs must accompany the frozen
specimen during air shipment. When dry ice is used,
the transport time should be minimized given that dry
APPENDIX 2 (Cont’d): PLASMA AND SERUM
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ice sublimates at a rate of 2 to 5 kg per 24 hours
depending on the insulation of the shipment container.
B. Consult the local agency for proper shipping options
and certified transport materials. The International Air
Transportation Association (http://www.iata.org) and the
U.S. Department of Transportation (http://www.dot.gov)
have legal requirements governing the packaging, la-
beling, and shipping of biospecimens.
i. Category A infectious substances are capable of
causing permanent disability or life-threatening or
fatal disease in humans or animals when exposure
occurs.
ii. Category B infectious substances (also “diagnostic
specimens” or “clinical specimens”) are infectious
but do not meet the standard for Category A inclu-
sion.
iii. Exempt patient specimens have a minimal likeli-
hood of containing pathogens.
D. Temperature loggers can be used to monitor tempera-
ture in shipments of samples to provide confirmation
and assurance that samples have been maintained at
appropriate temperatures.
VI. Central storage (see appendix 1)
APPENDIX 3: CSF GUIDELINE
I. Acquisition of CSF from an EVD
A. Document whether continuous or intermittent (catheter
opened only in response to intracranial hypertension)
fluid drainage is administered. Drainage method has
been shown to alter CSF protein concentration.21
B. Draw CSF directly from ventriculostomy catheter.
C. Target CSF collection within the first 24 hours of
admission, recording time from TBI and time of day.
Ideally, the first collection should be as close to the TBI
as feasible (eg, 6h post-TBI), at a minimum frequency
of every 6 hours for sufficient biokinetic studies.
D. Collect 5mL of CSF in 1-mL fractions and place in ice
bath. The first 1 or 2 fractions are sent for clinical
laboratory analysis for cell count and protein and glu-
cose measurements. Blood contamination of CSF is a
significant confounder. Protein concentrations are 400-
fold greater in plasma than CSF.22 CSF is considered
blood-contaminated if RBC counts are greater than 10
cells/L or if hemoglobin levels are greater than
30pg/mL CSF.23 Brain specific proteins are typically
present at low concentrations in CSF, with 80% of
normal CSF protein mass originating from plasma.24
E. Appropriate CSF control samples may be available
from hydrocephalic patients who undergo ventriculo-
peritoneal shunt placement and had CSF collected in-
traoperatively, or patients with unruptured subarachnoid
hemorrhage who had CSF drawn intraoperatively.25
II. Acquisition of CSF from an LP
A. In patients who are unlikely to receive a ventriculos-
tomy, CSF can be accessed by a less invasive LP. A
greater number of LP collected control samples are
available; however, comparison with EVD CSF is dis-
couraged given a 2.5-fold lower protein concentration
than in LP CSF.26
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B. Atraumatic spinal needle LP kits should be used to
minimize risk of post-LP headache. Draw with a sterile
polypropylene syringe or allow flow under gravity.
C. Target CSF collection within the first 24 hours after
admission, recording time from TBI and time of day.
Ideally, the first collection should be as close to the TBI
as feasible (eg, 6h post-TBI) at a minimum frequency
of every 6 hours for sufficient biokinetic studies.
D. Collect 1-mL fractions and place in ice bath, with a
maximum of 25mL a time point. Send the first 2mL for
clinical laboratory analysis. It is important to match frac-
tions when comparing across patients because protein
concentration varies depending on the draw volume.27
E. Patient should rest in a recumbent position for 1 hour
post-LP, receive liberal fluid intake, and avoid exertion
for 24 to 48 hours to minimize risk of headache.
III. Processing and storage of CSF
A. Transport CSF on ice and process immediately after
collection because significant cell lysis contamination
will occur within 1 hour.
B. Collect CSF samples into low protein binding polypro-
pylene tubes (eg, Eppendorf brand LoBind tubesc).
Avoid polystyrene and glass tubes, which will result in
significant protein loss.28
C. Centrifuge CSF at 2000g and 4°C for 10 minutes. Draw
off supernatant and place in new, low binding tube, and
document volume of fluid collected. Centrifugation
will only remove RBCs, not serum-derived proteins.
Samples found to contain greater than 10 RBCs/L
CSF may be inappropriate for proteomic analysis.
D. Control samples are available; however, comparison
with EVD CSF is discouraged given a 2.5-fold lower
protein concentration than in LP CSF.26
E. Additives or preservatives may be combined with CSF
depending on experimental objectives. Protease and
phosphatase inhibitors are recommended.
F. Snap freeze samples in liquid nitrogen, and store at or below
–80°C to minimize proteolytic breakdown.29 Avoid repeated
freeze and thawing cycles and storage at –20°C.30
APPENDIX 4: CEREBRAL MICRODIALYSIS
GUIDELINES
I. Probe placement
A. In TBI, placement in pericontusional at-risk tissue is
recommended, and if the option for placement of a
second probe is available, the second probe should be
placed in normal tissue.
B. Probe placement directly into contusions is of no
value.
C. In case of diffuse injury, probe placement should be in
the right frontal lobe.
II. Probe characteristics
A. Concentric configuration commercially available
probes are preferable to locally fabricated probes.
B. Low-molecular-weight cutoff probes have been in use
for many years and are available worldwide.31
C. Higher-molecular-weight cutoff probes are available
but have not passed regulatory clearance in all juris-
dictions, including the United States.
D. Probe molecular weight cutoff, manufacturer, and
model must be specified in all data reporting.
APPENDIX 4 (Cont’d): CEREBRAL
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III. Microdialysate characteristics
A. Either of the following microdialysate fluids is acceptable:
i. Artificial CSF
ii. Sterile medical-grade normal saline
B. The composition and source of the microdialysate
must be specified in all data reporting.
IV. Sample acquisition
A. The microdialysate flow rate should be 0.3L/min so
that it is theoretically possible to collect 18L during
1 hour. This flow rate assures near 100% analyte
recovery for common low-molecular-weight analytes.
B. Because of the extremely small sample volumes, the
samples are sensitive to evaporation even though they
are sealed in the microvials, and because microvials
may contain different volumes, the effect of evapora-
tion can vary between the samples. Characteristics of
the collecting containers must be reported.
C. Samples should be analyzed and/or stored promptly.
V. Analytes
A. The minimal essential data set consists of glucose, pyru-
vate, and lactate, with use of the calculated lactate/pyru-
vate ratio.
B. Measurement of glycerol and glutamate is recommended.
C. Determination of other analytes including markers of
neuroinflammation such as cytokines, nitrate and ni-
trite as surrogates for nitric oxide, structural proteins
such as glial fibrillary acidic protein, neurofilament,
and tau and stress reactants such as beta-amyloid are
all experimental. Analysis of these and other potential
biomarkers should be encouraged but not required.
VI. Analyte stability during storage
A. The essential low-molecular-weight analytes are stable at
–70°C. The samples should be stored at this temperature
in containers designed to minimize evaporative losses.
B. Analytes, particularly pyruvate, may not be stable at
–20°C. Storage at this temperature is not acceptable
with the exception of temporary holding for not more
than 3 days.
C. Determination of other analytes including markers of
neuroinflammation such as cytokines, nitrate and ni-
trite as surrogates for nitric oxide, structural proteins
such as GFAP, neurofilament, and tau and stress re-
actants such as beta-amyloid are all experimental.
Analysis of these and other potential biomarkers
should be encouraged but not required.
VII. Handling of samples at the time of analysis
A. If the samples have been frozen, then they must be
thawed prior to analysis. It is important to recognize
physicochemical events that may occur in the process of
thawing that might cause analytic errors. As the samples
thaw, the liquid phase will initially contain a very high
concentration of salt and analytes. As the thawing
progresses, the solution will be diluted by the melting ice.
During this process, there is a risk that the thawed sam-
ples are nonhomogeneous; therefore, it is recommended
that the samples be thawed and then agitated or centri-
fuged to assure homogeneous distribution of analyte.
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B. It may be desirable to thaw the samples rapidly in a heating
cupboard at 40°C for about 10 minutes. Longer times
and/or higher temperatures should not be used because
these may result in a risk for unacceptable evaporation.
C. Stored samples may be assayed using the batch analysis
systems. However, if the low-volume samples sit for too
long in the analyzer prior to analysis, unacceptable evap-
oration may occur. Calibration samples should be inter-
spersed in the batch to detect a systematic elevation in
analyte levels caused by evaporative loss.
VIII. Microdialysis data reporting
A. Analyte concentrations should be reported in Interna-
tional System (SI) units.
B. Ratios such as the lactate/pyruvate ratio are devoid of units.
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